Cloudbreak Pharma Inc. announced a material re-allocation of the HK$524.60 million net proceeds raised in its June 2025 global offering, shifting HK$103.60 million from the originally earmarked Phase III development of CBT-009 to other pipeline priorities and corporate needs. As at 22 May 2026, HK$212.00 million (40.40%) of the proceeds had been spent, leaving HK$312.60 million (59.60%) available for redeployment.

The revised plan lifts the aggregate budget for clinical R&D on lead assets CBT-001 and CBT-004 by HK$31.80 million to HK$359.20 million, of which HK$225.20 million remains unutilised. Allocation for the CBT-009/CBT-358/CBT-277 group falls to HK$84.10 million (previously HK$144.80 million), reflecting the voluntary withdrawal of the China IND application for CBT-009 and accelerated timelines for the new dry-eye candidates, CBT-358 and CBT-277. Approximately HK$57.60 million of this tranche is still unspent.

Manufacturing and commercialisation funding is unchanged at HK$28.80 million, with just HK$0.90 million left unutilised. Working capital and general corporate purposes rise to HK$52.50 million after a HK$28.90 million top-up, matching the forecast uptick in administrative costs linked to the broader clinical programme.

Management cited three drivers for the re-allocation: 1) regulatory divergence that prompted withdrawal of CBT-009’s multi-regional Phase III trial in China; 2) faster-than-expected IND-enabling progress for CBT-358 (IND filed with the U.S. FDA on 21 May 2026) and preparations for CBT-277; and 3) imminent Phase III and commercial-filing expenditures for flagship assets CBT-001 and CBT-004.

To reinforce governance over the remaining proceeds, Cloudbreak Pharma has upgraded its Investment Policy and instituted a board-level budget approval mechanism. All disbursements must align with the revised allocation and receive prior authorisation, with quarterly performance reviews and compliance checks against Hong Kong Listing Rules.

The board affirmed that the strategic shift does not alter the company’s business scope and positions the pipeline for more efficient capital deployment across assets sharing its proprietary SFA+ platform.